WHO temporarily pauses studying hydroxychloroquine due to safety concerns

The World Health Organization has temporarily halted studying hydroxychloroquine as a potential Covid-19 treatment in its Solidarity Trial due to safety concerns, WHO Director-General Tedros Adhanom Ghebreyesus said during a briefing in Geneva on Monday.

The decision was made after an observational study was published in the medical journal The Lancet on Friday, which described how seriously ill Covid-19 patients who were treated with hydroxychloroquine and chloroquine were more likely to die.

Five Things to Remember When Interpreting Epidemiologic Data

We know that the number of cases we have on record is an underrepresentation of the true burden for several reasons. Some underrepresentation is because testing for SARS-CoV-2 might not be available for the infected person… Another factor is that not everyone will need to see a doctor for COVID-19. The World Health Organization (WHO) published a very detailed report about the outbreak of COVID-19 in China and found that 80% of cases were mild or moderate. Since then, there have been studies that have identified infections in people who never develop symptoms. If someone gets infected and recovers on their own, then public health may never find out about the case.